Current status of Chagas disease chemotherapy

Successful Treatment with Posaconazole of a Patient with Chronic Chagas Disease and Systemic Lupus Erythematosus

(2010) María-Jesús Pinazo et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Effects of Ravuconazole Treatment on Parasite Load and Immune Response in Dogs Experimentally Infected with Trypanosoma cruzi

(2010) L. d. F. Diniz et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Nitric oxide donor trans-[RuCl([15]aneN4)NO]2+ as a possible therapeutic approach for Chagas' disease

(2010) Paulo MM Guedes et al.   BRITISH JOURNAL OF PHARMACOLOGY

Advances in Chagas disease drug development: 2009–2010

(2010) Frederick S Buckner et al.   CURRENT OPINION IN INFECTIOUS DISEASES

A comparative study of posaconazole and benznidazole in the prevention of heart damage and promotion of trypanocidal immune response in a murine model of Chagas disease

(2010) Bianca P. Olivieri et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Chagas disease

(2010) Anis Rassi et al.   LANCET

Clinical and laboratory status of patients with chronic Chagas disease living in a vector-controlled area in Minas Gerais, Brazil, before and nine years after aetiological treatment

(2010) Marta de Lana et al.   MEMORIAS DO INSTITUTO OSWALDO CRUZ

Experimental Chemotherapy against Trypanosoma cruzi Infection Using Ruthenium Nitric Oxide Donors

(2009) J. J. N. Silva et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

New Advances in the Management of a Long‐Neglected Disease

(2009) Julio A. Urbina   CLINICAL INFECTIOUS DISEASES

Molecular diagnosis and treatment monitoring of congenital transmission of Trypanosoma cruzi to twins of a triplet delivery

(2009) Juan M. Burgos et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Elimination of Chagas disease transmission: perspectives

(2009) João Carlos Pinto Dias   MEMORIAS DO INSTITUTO OSWALDO CRUZ

Trypanosoma cruzi: parasite antigens sequestered in heart interstitial dendritic cells are related to persisting myocarditis in benznidazole-treated mice

(2009) Renata Siqueira Portella et al.   MEMORIAS DO INSTITUTO OSWALDO CRUZ

The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease

(2009) J Antonio Marin-Neto et al.   MEMORIAS DO INSTITUTO OSWALDO CRUZ

Treatment and seroconversion in a cohort of children suffering from recent chronic Chagas infection in Yoro, Honduras

(2009) Josep M Escribà et al.   MEMORIAS DO INSTITUTO OSWALDO CRUZ

Efficacy of benznidazol treatment for asymptomatic chagasic patients from state of Rio Grande do Sul evaluated during a three years follow-up

(2009) CD Fernandes et al.   MEMORIAS DO INSTITUTO OSWALDO CRUZ

Ergosterol biosynthesis and drug development for Chagas disease

(2009) Julio A Urbina   MEMORIAS DO INSTITUTO OSWALDO CRUZ

A new consensus for Trypanosoma cruzi intraspecific nomenclature: second revision meeting recommends TcI to TcVI

(2009) B Zingales et al.   MEMORIAS DO INSTITUTO OSWALDO CRUZ

Current epidemiological trends for Chagas disease in Latin America and future challenges in epidemiology, surveillance and health policy

(2009) Álvaro Moncayo et al.   MEMORIAS DO INSTITUTO OSWALDO CRUZ

Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: The BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT)

(2008) Jose Antonio Marin-Neto et al.   AMERICAN HEART JOURNAL

Benznidazole therapy during acute phase of Chagas disease reduces parasite load but does not prevent chronic cardiac lesions

(2008) Ivo Santana Caldas et al.   PARASITOLOGY RESEARCH